Related Experiment Videos
Systemic lupus erythematosus in a child receiving long-term interferon therapy
A Tolaymat1, B Leventhal, A Sakarcan
1Department of Pediatrics, University of Florida Health Science Center, Jacksonville 32209.
The Journal of Pediatrics
|March 1, 1992
Summary
Systemic lupus erythematosus (SLE) developed in a young boy treated with interferon alfa-n1. This case suggests interferon therapy may trigger autoimmune disorders like drug-induced SLE.
Area of Science:
- Immunology
- Pediatric Autoimmunity
Background:
- Juvenile laryngeal papillomatosis is a rare condition in children.
- Interferon alfa-n1 is a biologic response modifier used in treating certain viral infections and cancers.
Observation:
- A 10-year-old boy with juvenile laryngeal papillomatosis developed systemic lupus erythematosus (SLE).
- The patient had undergone 7 years of interferon alfa-n1 therapy prior to SLE diagnosis.
Findings:
- The clinical presentation and rapid improvement upon discontinuation of interferon alfa-n1 and initiation of SLE treatment supported a diagnosis of drug-induced SLE.
- This case highlights a potential association between long-term interferon alfa-n1 therapy and the development of autoimmune disorders.
Implications:
- Interferon therapy may be a potential trigger for autoimmune diseases, including systemic lupus erythematosus, in susceptible individuals.
- Clinicians should consider interferon-induced autoimmunity in patients presenting with new-onset autoimmune symptoms during or after treatment.